We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Single Test Detects All Existing Strains of H5N1

By LabMedica International staff writers
Posted on 06 Jun 2012
A bird flu diagnostic kit was successfully developed by scientists at a research institute and a hospital in Singapore.

The advanced kit enables doctors to rapidly detect all existing strains of H5N1 viruses in a single test with almost 100% accuracy. This will boost the public healthcare system and will aid pandemic preparedness worldwide against this highly infectious and often lethal disease.

The new H5N1 test kit is more accurately known as the H5N1 real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay. It is the only detection kit currently available on the market that can accurately and rapidly detect all known strains of the H5N1 avian Influenza A virus.

The current gold standard for H5N1 detection recommended by the World Health Organization (WHO; Geneva, Switzerland) is only able to detect three out of the 10 distinct genetic groups (clades 1, 2, and 3). To detect all existing strains of H5N1 with the WHO detection method is not possible.

Codeveloped by Dr. Masafumi Inoue, a senior research scientist and project director of technology development from the Experimental Therapeutics Center (ETC) under the Agency for Science and Technology Research (A*STAR; Singapore) and Dr Timothy Barkham, a senior consultant of Laboratory Medicine from Tan Tock Seng Hospital (TTSH; Singapore), the newly launched H5N1 test kit has been clinically validated by several hospitals in Southeast Asia.

The new test kit is compatible with the previously launched "4-plex" Influenza diagnostic kit. The latter is being used by several regional hospitals in Thailand. Using such multiplex assays enables simultaneous detection and differentiation of the different types of influenza infection in a single test, which will save laboratories time and expense.

"We are excited to be able to contribute to the fight against H5N1 virus with our expertise and know-how. Our technology has greatly simplified and accelerated the process of detection and identification of new H5N1 variants. Such information is especially critical when the virus mutates to become more dangerous, such as in drug resistance." said Dr Inoue.

Related Links:

Agency for Science and Technology Research
Tan Tock Seng Hospital
World Health Organization


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
8-Channel Pipette
SAPPHIRE 20–300 µL

Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
INTEGRA BIOSCIENCES AG